These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 33844307)

  • 1. A generic emergency protocol for patients with inborn errors of metabolism causing fasting intolerance: A retrospective, single-center study and the generation of www.emergencyprotocol.net.
    Rossi A; Hoogeveen IJ; Lubout CMA; de Boer F; Fokkert-Wilts MJ; Rodenburg IL; van Dam E; Grünert SC; Martinelli D; Scarpa M; ; Dekker H; Te Boekhorst ST; van Spronsen FJ; Derks TGJ
    J Inherit Metab Dis; 2021 Sep; 44(5):1124-1135. PubMed ID: 33844307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term major clinical outcomes in patients with long chain fatty acid oxidation disorders before and after transition to triheptanoin treatment--A retrospective chart review.
    Vockley J; Marsden D; McCracken E; DeWard S; Barone A; Hsu K; Kakkis E
    Mol Genet Metab; 2015; 116(1-2):53-60. PubMed ID: 26116311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results from a 78-week, single-arm, open-label phase 2 study to evaluate UX007 in pediatric and adult patients with severe long-chain fatty acid oxidation disorders (LC-FAOD).
    Vockley J; Burton B; Berry GT; Longo N; Phillips J; Sanchez-Valle A; Tanpaiboon P; Grunewald S; Murphy E; Bowden A; Chen W; Chen CY; Cataldo J; Marsden D; Kakkis E
    J Inherit Metab Dis; 2019 Jan; 42(1):169-177. PubMed ID: 30740733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UX007 for the treatment of long chain-fatty acid oxidation disorders: Safety and efficacy in children and adults following 24weeks of treatment.
    Vockley J; Burton B; Berry GT; Longo N; Phillips J; Sanchez-Valle A; Tanpaiboon P; Grunewald S; Murphy E; Humphrey R; Mayhew J; Bowden A; Zhang L; Cataldo J; Marsden DL; Kakkis E
    Mol Genet Metab; 2017 Apr; 120(4):370-377. PubMed ID: 28189603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and biological features at diagnosis in mitochondrial fatty acid beta-oxidation defects: a French pediatric study of 187 patients.
    Baruteau J; Sachs P; Broué P; Brivet M; Abdoul H; Vianey-Saban C; Ogier de Baulny H
    J Inherit Metab Dis; 2013 Sep; 36(5):795-803. PubMed ID: 23053472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Major clinical events and healthcare resource use among patients with long-chain fatty acid oxidation disorders in the United States: Results from LC-FAOD Odyssey program.
    Yang E; Kruger E; Yin D; Mace K; Tierney M; Liao N; Cibelli E; Drozd D; Ross N; Deering KL; Herout P; Harshaw Q; Shillington A; Thomas N; Marsden D; Kritzer A; Vockley J
    Mol Genet Metab; 2024 May; 142(1):108350. PubMed ID: 38458123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A preliminary study of telemedicine for patients with hepatic glycogen storage disease and their healthcare providers: from bedside to home site monitoring.
    Hoogeveen IJ; Peeks F; de Boer F; Lubout CMA; de Koning TJ; Te Boekhorst S; Zandvoort RJ; Burghard R; van Spronsen FJ; Derks TGJ
    J Inherit Metab Dis; 2018 Nov; 41(6):929-936. PubMed ID: 29600495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follow-up of fatty acid β-oxidation disorders in expanded newborn screening era.
    Janeiro P; Jotta R; Ramos R; Florindo C; Ventura FV; Vilarinho L; Tavares de Almeida I; Gaspar A
    Eur J Pediatr; 2019 Mar; 178(3):387-394. PubMed ID: 30617651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of triheptanoin (UX007) in patients with long-chain fatty acid oxidation disorders: Results from an open-label, long-term extension study.
    Vockley J; Burton B; Berry G; Longo N; Phillips J; Sanchez-Valle A; Chapman K; Tanpaiboon P; Grunewald S; Murphy E; Lu X; Cataldo J
    J Inherit Metab Dis; 2021 Jan; 44(1):253-263. PubMed ID: 32885845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective Screening of Fatty Acids Oxidation Defects and Organic Acidemias by Liquid Chromatography/tandem Mass Spectrometry Acylcarnitine Analysis in Brazilian Patients.
    Vargas CR; Ribas GS; da Silva JM; Sitta A; Deon M; de Moura Coelho D; Wajner M
    Arch Med Res; 2018 Apr; 49(3):205-212. PubMed ID: 30119976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triheptanoin treatment in patients with pediatric cardiomyopathy associated with long chain-fatty acid oxidation disorders.
    Vockley J; Charrow J; Ganesh J; Eswara M; Diaz GA; McCracken E; Conway R; Enns GM; Starr J; Wang R; Abdenur JE; Sanchez-de-Toledo J; Marsden DL
    Mol Genet Metab; 2016 Nov; 119(3):223-231. PubMed ID: 27590926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor binding protein-1 levels in the diagnosis of hypoglycemia caused by hyperinsulinism.
    Levitt Katz LE; Satin-Smith MS; Collett-Solberg P; Thornton PS; Baker L; Stanley CA; Cohen P
    J Pediatr; 1997 Aug; 131(2):193-9. PubMed ID: 9290603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heat stress deteriorates mitochondrial beta-oxidation of long-chain fatty acids in cultured fibroblasts with fatty acid beta-oxidation disorders.
    Li H; Fukuda S; Hasegawa Y; Purevsuren J; Kobayashi H; Mushimoto Y; Yamaguchi S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Jun; 878(20):1669-72. PubMed ID: 20207594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-invasive test using palmitate in patients with suspected fatty acid oxidation defects: disease-specific acylcarnitine patterns can help to establish the diagnosis.
    Janzen N; Hofmann AD; Schmidt G; Das AM; Illsinger S
    Orphanet J Rare Dis; 2017 Dec; 12(1):187. PubMed ID: 29268767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical manifestations and management of fatty acid oxidation disorders.
    Merritt JL; MacLeod E; Jurecka A; Hainline B
    Rev Endocr Metab Disord; 2020 Dec; 21(4):479-493. PubMed ID: 32654032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective review of anesthesia and perioperative care in children with medium-chain acyl-CoA dehydrogenase deficiency.
    Allen C; Perkins R; Schwahn B
    Paediatr Anaesth; 2017 Jan; 27(1):60-65. PubMed ID: 27896927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newborn screening for disorders of fatty-acid oxidation: experience and recommendations from an expert meeting.
    Lindner M; Hoffmann GF; Matern D
    J Inherit Metab Dis; 2010 Oct; 33(5):521-6. PubMed ID: 20373143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inborn Errors of Metabolism with Hypoglycemia: Glycogen Storage Diseases and Inherited Disorders of Gluconeogenesis.
    Weinstein DA; Steuerwald U; De Souza CFM; Derks TGJ
    Pediatr Clin North Am; 2018 Apr; 65(2):247-265. PubMed ID: 29502912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed diagnosis of fatal medium-chain acyl-CoA dehydrogenase deficiency in a child.
    Shetty AK; Craver RD; Harris JA; Schmidt-Sommerfeld E
    Pediatr Emerg Care; 1999 Dec; 15(6):399-401. PubMed ID: 10608324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired amino acid metabolism contributes to fasting-induced hypoglycemia in fatty acid oxidation defects.
    Houten SM; Herrema H; Te Brinke H; Denis S; Ruiter JP; van Dijk TH; Argmann CA; Ottenhoff R; Müller M; Groen AK; Kuipers F; Reijngoud DJ; Wanders RJ
    Hum Mol Genet; 2013 Dec; 22(25):5249-61. PubMed ID: 23933733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.